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Abstract
Background: Cluster (CRTs) and individually randomized trials (IRTs) are often pooled
together in meta-analyses (MAs) of randomized trials. However, the potential systematic
differences in intervention effect estimates between these two trial types has never been
investigated. Therefore, we conducted a meta-epidemiological study comparing inter-
vention effect estimates between CRTs and IRTs.
Methods: All Cochrane MAs including at least one CRT and one IRT, published between
1 January 2010 and 31 December 2014, were included. For each MA, we estimated a ratio
of odds ratios (ROR) for binary outcomes or a difference of standardized differences
(DSMD) for continuous outcomes, where less than 1 (or 0, respectively) indicated a
greater intervention effect estimate with CRTs.
Results: Among 1301 screened reviews, we selected 121 MAs, of which 76 had a binary
outcome and 45 had a continuous outcome. For binary outcomes, intervention effect
estimates did not differ between CRTs and IRTs [ROR 1.00, 95% confidence interval (0.93
to 1.08)]. Subgroup and adjusted analyses led to consistent results. For continuous out-
comes, the DSMD was 0.13 (0.06 to 0.19). It was lower for MAs with a pharmacological
intervention [-0.03, (-0.12 to 0.07)], an objective outcome [0.05, (-0.08 to 0.17)] or after
adjusting for trial size [0.06, (-0.01 to 0.15)].
Conclusion: For binary outcomes, CRTs and IRTs can safely be pooled in MAs because of
an absence of systematic differences between effect estimates. For continuous
outcomes, the results were less clear although accounting for trial sample sizes led to
a non-significant difference. More research is needed for continuous outcomes and,
meanwhile, MAs should be completed with subgroup analyses (CRTs vs IRTs).
VC The Author(s) 2018. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
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Introduction
Cluster randomized trials (CRTs) are defined as trials in
which clusters of participants such as wards, practices,
schools or villages are randomized rather than the partici-
pants themselves.1 These trials are known to be more sus-
ceptible to bias than individually randomized trials (IRTs).
For instance, recruitment bias may occur when partici-
pants are recruited after cluster randomization by a non-
blinded recruiter.2–6 This situation shares some similarities
with the lack of allocation concealment, shown to be asso-
ciated with an over-estimation of intervention effects.7 In
this situation, study groups may be unbalanced in regard
to individual baseline characteristics, as the individual is
not the unit of randomization.
Some interventions have been assessed with both CRTs
and IRTs. In two reviews of hip protectors, large positive
effects were seen in CRTs whereas effects in IRTs were
more equivocal.8,9 Although the intervention assessed may
appear simple, Hahn et al.9 explained that it actually may
differ in two ways between CRTs and IRTs: (i) CRTs may
benefit from a ‘herd effect’ with higher compliance; and (ii)
IRTs may suffer from inter-group contamination which is
often a reason for adopting cluster randomization. Both
elements could lead to larger intervention effect estimates
in CRTs than in IRTs. Conversely, Gilbody et al.10 found
similar results between CRTs and IRTs when investigating
collaborative care for depression, and Selvaraj and
Prasad11 found similar proportions of positive results be-
tween CRTs and IRTs
These examples remain anecdotal, and to date we lack
general findings as to whether intervention effect estimates
are, on average, larger in CRTs than in IRTs. It then
remains unclear whether these trial types can be pooled in
meta-analyses (MAs). The Cochrane Handbook12 considers
the unit-of-analysis error for CRTs, but nothing is said
regarding a potential systematic difference in intervention
effect estimates between these two trial types. Knowing if
such a difference exists is, however, crucial for different
reasons. First, CRTs and IRTs are often meta-analysed to-
gether, but this relies on the assumption that they estimate
the same quantity of interest. Second, if there is a system-
atic difference between the estimates from the two types of
trials, it might suggest that CRTs and IRTs lead to different
estimands and therefore the interpretations of the results
are different; CRTs keep existing ‘social units’ in which
participants can interact. Therefore, CRTs may lead to
real-world evidence and estimation of the effectiveness,
as opposed to the ‘ideal-world’ estimation of efficacy
obtained from IRTs. Third, the presence of systematic dif-
ferences would imply that the intervention effect estimates
from an IRT could not be used (at least as it is) to inform
the sample size of a future CRT and vice versa.
For these reasons, we performed a meta-epidemiological
study to assess whether intervention effect estimates are
larger in CRTs than in IRTs. With this approach, we aim to
understand whether the specificities of the two types of trials
lead to systematic differences in intervention effect esti-
mates. Indeed, CRTs and IRTs not only differ in the ran-
domization procedure but also in ways participants are
recruited, the intervention delivered, etc. Hence, we want to
quantify the overall impact of these differences on the inter-
vention effect estimates. To do so, we compared interven-
tion effect estimates for the same intervention on the same
outcome in studies using cluster randomization and
studies using individual randomization. In order to ensure a
comparability of the intervention and outcomes, we used tri-
als that have been meta-analysed together in systematic
reviews, adopting a quantitative approach called a meta-
epidemiological study.
Key Messages
• Cluster randomized trials are known to be more pragmatic than individually randomized trials but also more suscepti-
ble to bias.
• Cluster randomized and individually randomized trials are often pooled in MAs, but no study has investigated
potential systematic differences in intervention effect estimates between these two trial types.
• In MAs of binary outcomes, intervention effect estimates for cluster and individually randomized trials did not differ.
• In MAs of continuous outcomes, intervention effect estimates were moderately more favourable for individually ran-
domized trials. However, the difference in intervention effects was moderated by study size and characteristics of out-
come and intervention. Therefore, the inconsistent results in subgroup analyses invite further studies.
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Methods
Meta-epidemiological studies are used to determine which
trial characteristics are associated with treatment effect
estimates.13 In this study, the characteristic of interest is
the design (cluster vs individual randomization). A meta-
epidemiological study is generally conducted with a two-
step approach using a collection of MAs. First, for each se-
lected MA and considering the trial as the unit of analysis,
the difference in intervention effect estimates between
studies which have the characteristic of interest (i.e. which
are cluster randomized, in the present study) and those
which are not, is assessed. This is done by fitting one
meta-regression for each selected MA. Second, results
obtained after this first step are meta-analysed. In this sec-
ond step, the units of analysis are the MAs which have ini-
tially been selected. Using this approach, our null
hypothesis for our primary analysis was an absence of a
systematic difference in intervention effect estimates be-
tween CRTs and IRTs.
Data sources
On 10 March 2015, we searched for eligible MAs pub-
lished between 1 January 2010 and 31 December 2014 in
the Cochrane Database of Systematic Reviews, by using
the following keywords: ‘cluster randomized’ OR ‘group
randomized’ OR ‘community randomized’ in the full
text.
MA and trial selection
Identified systematic reviews were screened to select only
those including both CRTs and IRTs. We selected eligible
MAs with at least three randomized trials, including at
least one CRT and one IRT. Where more than one MA
was eligible within the same review, the MA corresponding
to the primary outcome, if clearly stated, was selected.
Otherwise, the MA with the largest number of trials was
selected. We excluded MAs with safety or compliance out-
comes and those for which a control group was not clearly
identifiable.
Trials were classified as CRT or IRT according to what
was reported in the systematic review. Because we were in-
terested in comparing trials that used different randomiza-
tion units, we discarded quasi-randomized trials and
controlled before–after studies. We discarded duplicate tri-
als within MAs and kept the duplicate with the largest
sample size. We finally discarded duplicate trials between
MAs, keeping the duplicate from the most recently pub-
lished systematic review. All those steps were performed
independently by two of us (C.L., B.G.), with
disagreements resolved by discussion, referring to a third
opinion (A.C.) when necessary.
Data extraction and coding
We extracted data related to MAs and trials by using two
standardized and pilot-tested spreadsheets. The items we
extracted are presented in Supplementary Table 1, avail-
able as Supplementary data at IJE online. Data were col-
lected from the systematic reviews, except when
otherwise specified. Data extraction was performed inde-
pendently by two of us (C.L., B.G.) and any discrepancy
was adjudicated, referring to a third opinion (A.C.) when
necessary.
If the number of patients per group, number of
events, means and standard deviations were not reported
in the systematic review, we collected them from the
trial reports, or in case of doubt, we contacted the
authors of the systematic reviews (which happened for
nine MAs).
Statistical analysis
Accounting for clustering: calculating effective
sample size
For CRTs which did not adjust for clustering during analy-
sis, we applied the method described in the Cochrane
Handbook12; the sample size of the trial was reduced to an
effective sample size by dividing the original sample size
by the design effect. The design effect is defined as [1 þ (M
– 1) q], where M is the average cluster size and q the intra-
class correlation coefficient (ICC), the parameter classi-
cally used to quantify the clustering effect. We collected
the ICC from the trial report and, if not reported, a value
of 0.03 was chosen, corresponding to the median ICC
value for outcome variables observed in the Campbell
et al.14 review. A sensitivity analysis doubled this generic
value to 0.06 and also considered two extreme situations
of no correlation (ICC¼ 0) and a very strong correlation
(ICC¼ 0.50). If clustering was accounted for, we col-
lected the effective sample size reported in the systematic
review.
Estimation of intervention effects within each MA
For binary outcomes, intervention effects estimates were
expressed as odds ratios. For all outcomes, an odds ratio of
less than 1 indicated a beneficial effect of the experimental
intervention. For continuous outcomes, intervention effects
estimates were expressed as standardized mean differences
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using the Hedges and Olkin unbiased estimator of effect
size:15
g ¼ 1 3
4 n1 þ n2  2ð Þ  1
 
d;
where n1 and n2 are the size of the control and experimen-
tal group, respectively, and d is the traditional Cohen’s
standardized difference:
d ¼ X1 X2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n11ð Þs21þ n21ð Þs22
n1n22
q :
X1 and X2 are the observed means in the control and
experimental group, respectively, and s21 and s
2
2 are the two
sample variance estimates. An effect of less than 0 always
indicated a beneficial effect of the experimental interven-
tion. For each MA, the intervention effect was estimated
by using a random effect MA.
Meta-epidemiologic analyses
We analysed binary and continuous outcomes separately,
using the two-step approach proposed by Sterne et al.16
First, for each MA, we performed an inverse-variance
weighted random effects meta-regression, thus
accounting for between-trial heterogeneity. The only co-
variate was the type of trial (cluster or individual randomi-
zation), with individual randomization as the reference
category. For binary outcomes, we estimated the ratio of
odds ratios (ROR), where a ratio of odds ratios less than 1
indicated more favourable intervention effect estimates in
cluster trials, meaning that either the intervention was
more beneficial or less detrimental in CRTs than in IRTs.
For continuous outcomes, we estimated the difference in
standardized mean differences (DSMD), where less than 0
indicated more favourable intervention effect estimates in
cluster trials. In the second stage, the ratio or difference in
intervention effects was combined across MAs
using random effects MAs. The heterogeneity between
MAs was quantified with the I2, Cochran Q chi-squared
test, and between MAs variance s2 17 using a REML esti-
mation.18 Analyses involved use of SAS 9.4 and R 3.2.0
with the package metafor. All the statistical tests were
done at a 5% significance level.
Subgroup and adjusted analyses
The type of outcome (objective vs subjective) was a pre-
specified subgroup analysis motivated by the fact that
Savovic et al.7 observed differences in their meta-meta-
epidemiological study according to whether the outcome
was an objective one or not, especially when looking at
blinding. The type of intervention (pharmacological vs
non-pharmacological) and control intervention (active vs
inactive) were post hoc subgroup analyses. For these sub-
group analyses, interaction P-values were obtained fitting
a random effects meta-regression model with MAs as the
unit of analysis and including the variable defining the sub-
group. Then, the ROR or DSMD was estimated separately
in each subgroup. Planned sensitivity analyses involved
adjusting the meta-regression models on each domain of
the Risk of Bias tool.19 We adjusted the analysis using each
item one at a time, considering low vs high or unclear risk.
Further post hoc sensitivity analyses were also conducted
adjusting on trial sample size. Adjusted analyses were con-
ducted excluding MAs with missing data.
Sample size calculation
In order to detect a ratio of odds ratio of 0.85, we required
57 MAs to achieve 80% power using a two-sided 5% sig-
nificance level,20 assuming a mean number of eight trials
per MA21 with an average of three being CRTs, and the
following variances: 0.25 for the within-trial variance of
the intervention effect estimate; 0.08 for the between-trial
within-meta-analysis variance of the intervention effect es-
timate; 0.0256 for the between-trial variance of the trial-
specific impact of the cluster vs individual randomization;
and 0.0016 for the between-meta-analysis variance of the
trial-specific impact of cluster randomization. These
assumptions were based on the Turner et al.22 large epide-
miological study of Cochrane MAs. Such a sample size cal-
culation supposes a binary outcome. We decided to
perform two separate analyses, according to whether the
outcome was binary or continuous, and then aimed at
identifying at least 57 MAs with a binary outcome.
Results
Characteristics of selected MAs
Considering Cochrane reviews published over a period of
five full years, we identified 1301 systematic reviews by the
electronic search. We selected 121 MAs (full references in in
the Supplementary Material 1a, 1b and 2, available as
Supplementary data at IJE online), corresponding to 1458
trials (Figure 1): 76 MAs (917 trials) had binary outcomes
and 45 (541 trials) had continuous outcomes. MAs con-
cerned very different medical and educational fields and
interventions (Supplementary Material 1a and 1b, available
as Supplementary data at IJE online).
Table 1 shows that pharmacological interventions
were investigated in 25 (32.5%) MAs with a binary
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outcome but in only six (13.3%) of those with a continu-
ous outcome. Less than one-third of the MAs had active
controls, both for binary and continuous outcomes.
Assessed outcomes were objective in one-third of MAs
with a binary outcome and in one-quarter with a continu-
ous outcome. The median number of trials (interquartile
range: IQR) included was 8 (5 to 15) for MAs with a bi-
nary outcome and 10 (5 to 14) for those with a continu-
ous outcome. Finally, for MAs with a continuous
outcome, more than half showed substantial heterogene-
ity, as defined in the Cochrane Handbook,12 with median
I2 of 60.4% (IQR 22.8%; 81.7%), whereas for MAs with
a binary outcome, the median I2 was 26.5% (IQR 0.0%;
53.5%).
Characteristics of selected trials
Among the 917 trials with a binary outcome, 183
(20.0%) were CRTs and 734 (80.0%) were IRTs
(Table 1). The median sample size was 570 for CRTs (213
to 1764) and 208 for IRTs (83 to 527). The median number
of randomized clusters was 31 (12 to 76) and in half, ran-
domized clusters correspond to clinical settings. For 64 of
them we used the 0.03 generic value for the ICC to correct
the sample size.
Among the 541 trials with a continuous outcome, 131
(24.2%) were CRTs and 410 (75.8%) were IRTs. The
median sample size was 139 for CRTs (55 to 291) and
113 for IRTs (56 to 211). Among the 131 CRTs, the me-
dian number of randomized clusters was 20 (10 to 40)
Figure 1. Flow diagram of the selection of MAs and randomized trials.
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and in less than one-third, randomized clusters corre-
sponded to clinical settings (Table 1). For 45 of them we
used the 0.03 generic value for the ICC to correct the
sample size.
For MAs with a continuous outcome, 30 CRTs
(23.4%) were at low risk of bias for blinding of
outcome assessment as compared with 161 IRTs
(40.4%), although in most of these, the risk was assessed
as unclear (Supplementary Table 2, available as
Supplementary data at IJE online). For binary outcomes,
no difference was observed between CRTs and IRTs in
terms of risk of bias.
Table 1. Characteristics of MAs and trials included
MA characteristics MAs with a binary outcome MAs with a continuous outcome
(n¼76) (n¼45)
Intervention, n (%)
Pharmacological 25 (32.9) 6 (13.3)
Non-pharmacological 51 (67.1) 39 (86.7)
Intervention in control group, n (%)
Inactive 52 (68.4) 34 (75.6)
Active 24 (31.6) 11 (24.4)
Outcome objectivity, n (%)
All-cause mortality 14 (18.4) -
Objectively assessed 11 (14.5) 11 (24.4)
Objectively assessed but influenced by clinician or patient 30 (39.5) 5 (11.1)
Subjectively assessed 21 (27.6) 29 (64.4)
Number of trials, median (first and third quartiles) (range)a
Total 8 (5; 15) (3 to 46) 10 (5; 14) (3 to 44)
Cluster randomized trial 2 (1; 3) (1 to 9) 1 (1; 2) (1 to 24)
Individually randomized trial 6 (3; 14) (1 to 45) 7 (3; 10) (1 to 38)
I2, median (first and third quartiles)a 26.5 (0.0; 53.5) 60.4 (22.8; 81.7)
s2, median (first and third quartiles)a 0.031 (0.000; 0.141) 0.039 (0.005; 0.156)
Binary outcome Continuous outcome
Trial characteristics CRTs IRTs CRTs IRTs
(n ¼ 183) (n ¼ 734) (n ¼ 131) (n ¼ 410)
Year of publication, median (first and third quartiles) 2003 (1997; 2008) 2003 (1996; 2007) 2006 (2003; 2009) 2006 (2001; 2009)
Sample size,a median (first and third quartiles) 570 (213; 1764) 208 (83; 527) 139 (55; 291) 113 (56 ; 211)
Mean6 standard deviation (SD) 7 8866 43 120 1 5896 9 059 280 6 424 197 6 354
Cluster type, n (%)
Clinical setting: 94 (51.4) 43 (32.8)
Hospital 12 (6.6) 4 (3.0)
Ward 11 (6.0) 3 (2.3)
Health centre 13 (7.1) 1 (0.8)
Residential care home 10 (5.5) 5 (3.8)
Practice or health professional 43 (23.5) 24 (18.3)
Other 5 (2.7) 6 (4.6)
Non-clinical setting: 85 (46.4) 87 (66.4)
School or classroom 20 (10.9) 63 (48.1)
Family/household 12 (6.6) 4 (3.0)
Village or geographical area 37 (20.2) 5 (3.8)
Other 16 (8.7) 15 (11.5)
Unclear 4 (2.2) 1 (0.8)
Number of clusters, median (first and third quartiles), (range) 31 (12; 76), 20 (10; 40),
(2 to 68 146) (4 to 531)
aFor CRTs, sample size was corrected for clustering.
CRT: cluster randomised trial, IRT: individually randomized trial.
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Figure 2. Differences in intervention effect estimates between cluster and individually randomized trials with a binary outcome.
International Journal of Epidemiology, 2018, Vol. 0, No. 0 7
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyy229/5168507 by guest on 13 N
ovem
ber 2018
Differences in intervention effect estimates
between CRTs and IRTs
For MAs with a binary outcome, intervention effect esti-
mates did not differ between CRTs and IRTs. The com-
bined ROR was estimated at 1.00 (95% CI 0.93 to 1.08)
(Figure 2 and Table 2). Heterogeneity was low across MAs
(I2 ¼ 21.2%; P¼ 0.238; between-meta-analyses variance
s2¼0.018). Subgroup and adjusted analyses led to consis-
tent results with a combined ROR very close to 1.00,
whatever the analysis (Table 2 and Supplementary Figures
2–4, available as Supplementary data at IJE online). The
results were also robust across all the performed sensitivity
analyses (see Supplementary Tables 3–5, available as
Supplementary data at IJE online).
For MAs with a continuous outcome, intervention ef-
fect estimates were more favourable for IRTs, with a com-
bined DSMD of 0.13 (95% CI 0.06 to 0.19) (Figure 3).
Although statistically significant, this different is small
according to Cohen’s classification of effect sizes23
Heterogeneity was low across MAs (I2 ¼ 21.7%;
P¼ 0.221; between-meta-analyses variance s2¼0.009).
Subgroup analyses led to inconsistent results among
subgroups. The combined DSMD was significant for non-
pharmacological interventions but was lower and non-
significant for pharmacological interventions: 0.15
(0.08 to 0.21) vs -0.03 (-0.12 to 0.07) (interaction P-
value¼ 0.016). Similarly, the effect of cluster randomiza-
tion on intervention effect estimates was larger for subjec-
tive than for objective outcomes, although the interaction
Table 2. Difference in intervention effect estimates between cluster and individually randomized trials for binary and continuous
outcomes
ROR Heterogeneity
Binary outcome n* Estimate 95% CI P-value I2 (95% CI) s2 (95% CI) P-value
Global 76 1.00 (0.93 to 1.08) 0.238 21.2 (0.0 to 41.4) 0.018 (0.000 to 0.047)
Subgroup analyses
Pharmacological 25 1.02 (0.94 to 1.10) 0.405 0.0 (0.0 to 64.9) 0.000 (0.000 to 0.103) 0.360
Non-pharmacological 51 0.98 (0.89 to 1.08) 0.218 20.9 (0.0 to 43.9) 0.023 (0.000 to 0.067)
Subjective 51 0.99 (0.89 to 1.10) 0.090 26.9 (0.0 to 48.9) 0.035 (0.000 to 0.902) 0.496
Objective 25 1.00 (0.93 to 1.08) 0.738 0.0 (0.0 to 49.3) 0.000 (0.000 to 0.047)
Active 24 1.02 (0.89 to 1.15) 0.657 6.0 (0.0 to 43.0) 0.006 (0.000 to 0.072) 0.929
Inactive 52 1.01 (0.91 to 1.11) 0.114 29.0 (0.0 to 57.6) 0.025 (0.000 to 0.083)
Adjusted on risk of bias of:
Generation of random sequence 60 1.03 (0.94 to 1.12) 0.005 37.8 (5.6 to 63.6) 0.034 (0.003 to 0.097)
Allocation concealment 60 1.01 (0.92 to 1.11) 0.012 37.1 (2.6 to 59.2) 0.034 (0.002 to 0.084)
Blinding for participants 31 1.01 (0.87 to 1.18) 0.001 53.0 (14.2 to 80.1) 0.062 (0.009 to 0.220)
Blinding for the outcome assessor 44 0.99 (0.89 to 1.11) 0.014 40.8 (2.6 to 63.0) 0.040 (0.002 to 0.099)
Adjusted on trial sample size 69 0.98 (0.89 to 1.07) 0.056 27.1 (0.0 to 58.3) 0.028 (0.000 to 0.105)
DSMD Heterogeneity
Continuous outcome n* Estimate 95% CI P-value I2 (95% CI) s2 (95% CI) P-value
Global 45 0.13 (0.06 to 0.19) 0.221 21.7 (0.0 to 47.4) 0.009 (0.000 to 0.029)
Subgroup analyses
Pharmacological 6 0.03 (-0.12 to 0.07) 0.435 0.0 (0.0 to 90.6) 0.000 (0.000 to 0.436) 0.016
Non pharmacological 39 0.15 (0.08 to 0.21) 0.515 7.5 (0.0 to 43.2) 0.003 (0.000 to 0.027)
Subjective 34 0.15 (0.08 to 0.22) 0.398 11.1 (0.0 to 52.5) 0.005 (0.000 to 0.040) 0.118
Objective 11 0.05 (-0.08 to 0.17) 0.420 20.5 (0.0 to 74.2) 0.008 (0.000 to 0.091)
Active 11 0.25 (0.15 to 0.36) 0.877 0.0 (0.0 to 57.2) 0.000 (0.000 to 0.049) 0.006
Inactive 34 0.08 (0.01 to 0.15) 0.352 15.4 (0.0 to 54.5) 0.006 (0.000 to 0.037)
Adjusted on risk of bias of:
Generation of random sequence 32 0.12 (0.05 to 0.19) 0.583 8.8 (0.0 to 48.0) 0.003 (0.000 to 0.031)
Allocation concealment 36 0.11 (0.03 to 0.19) 0.116 29.3 (0.0 to 60.9) 0.013 (0.000 to 0.050)
Blinding for participants 16 0.11 (0.00 to 0.22) 0.065 38.3 (0.0 to 78.9) 0.016 (0.000 to 0.094)
Blinding for the outcome assessor 23 0.22 (0.03 to 0.41) <0.0001 84.6 (66.7 to 93.0) 0.134 (0.049 to 0.328)
Adjusted on trial sample size 38 0.06 (-0.02 to 0.13) 0.060 24.1 (0.0 to 75.1) 0.011 (0.000 to 0.102)
n*, number of MAs included in the analysis.
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was not significant: 0.15 (0.08 to 0.22) vs 0.05 (-0.08 to
0.17) (interaction P-value ¼ 0.118). Finally, the DSMD
was significantly lower for inactive compared with active
control interventions: 0.08 (0.01 to 0.15) vs 0.25 (0.15 to
0.36) (interaction P-value ¼ 0.006). Adjusting for the
effective trial sample size led to a smaller difference of
0.06 (-0.02 to 0.13), which was not significant. Adjusting
for risk of bias items did not affect the results, except
for blinding of outcome assessors, with a higher DSMD,
estimated to be 0.22 (0.03 to 0.41). The choice of the ICC
value to adjust for clustering when the trials values
were not known does not impact the results (results are
presented in Supplementary Table 3, available as
Supplementary data at IJE online).
Discussion
In this meta-epidemiological study, we selected 121 MAs: 76
(917 trials) with a binary and 45 (541 trials) with continuous
outcomes. For binary outcomes, the ratio of odds ratios was
1.00 (95% CI 0.93 to 1.08), indicating that intervention ef-
fect estimates did not systematically differ between CRTs
and IRTs. Consistent results were observed in all subgroup
and adjusted analyses. For continuous outcomes, interven-
tion effect estimates were more favourable with individual
randomization, although the difference was moderate (dif-
ference in standardized mean differences of 0.13, 95% CI
0.06 to 0.19). This difference was much smaller and not sig-
nificant for the trial subgroup of pharmacological interven-
tions or when adjusting on sample size.
Strengths and limitations of the study
We selected a large sample of MAs covering a wide range of
medical and educational areas, which provides good gener-
alizability of our results. We nevertheless restricted our
study to Cochrane MAs: to identify potentially eligible
MAs, we had to access the full text of the systematic reviews
Figure 3. Differences in intervention effect estimates between cluster and individually randomized trials with a continuous outcome.
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because the abstracts of reports rarely specify the inclusion
of both CRTs and IRTs. Restricting our study to Cochrane
reviews may limit the generalizability of our results. This
study was conducted using trial-level summaries of the in-
tervention effect. Therefore, no information was available
regarding patients’ non-adherence or loss to follow-up,
which might have had an impact on the trials’ results, if
these issues were to affect CRTs differently from IRTs.
However, our aim was to assess whether there exists sys-
tematic differences between CRTs and IRTs. Further studies
using individual patient data would be needed to investigate
the specific effect of each component that differs between
CRTs and IRTs. Such studies would probably need to re-
strict the focus to a specific medical area, which differs from
the philosophy of meta-epidemiological studies.
We discarded studies not randomized, such as quasi-
randomized trials or before–after studies, so as to obtain
well-defined groups for comparison. We handled cluster-
ing, thus making sure that our results were not distorted by
over-weighted CRTs. Finally we explored both binary and
continuous outcomes in the same study (although indepen-
dently) which, except for the Alexander et al.24 or Smaı¨l-
Faugeron et al.25 studies, is uncommon.
Relation to previous work
To our knowledge and in view of the Dechartres et al.26 re-
cently published systematic review of meta-epidemiological
studies, our study is the first meta-epidemiological study to
compare intervention effect estimates between CRTs and
IRTs. However, our results are consistent with Selvaraj and
Prasad’s,11 who showed that the proportions of statistically
significant findings were similar in CRTs and IRTs.
Possible mechanisms
CRTs and IRTs differ in several ways. CRTs may face recruit-
ment bias, but they may benefit from a ‘herd effect’; IRTs may
suffer from group contamination. All these elements may lead
to larger intervention effect estimates in CRTs than in IRTs.
Besides, most of the interventions assessed in CRTs do not al-
low for any form of blinding, which invites both performance
and detection bias.6 This feature has been shown to be associ-
ated with an over-estimation of intervention effects.7
Conversely, CRTs are considered more pragmatic,27 and al-
low the estimation of the effectiveness, rather than the effi-
cacy, as in many IRTs. Effectiveness is usually smaller than
efficacy, mainly because of non-compliance. Pragmatic trials
also nearly always involve several centres and they are usually
larger. These characteristics are important because the inter-
vention effect estimates have been shown to be lower in multi-
centre than single-centre trials,28,29 and in larger trial sample
sizes.30 Therefore, antagonist mechanisms may occur and
might counterbalance each other. In the end, although CRTs
and IRTs may look as if they are similar but just conducted as
CRTs or IRTs, very different mechanisms—sometimes antag-
onist—may apply and contribute to systematic differences in
intervention effect estimates between CRTs and IRTs.
Discrepancy between binary and continuous
outcomes
The finding that there is no difference between CRTs and
IRTs for binary outcomes suggests that the different mecha-
nisms are not very strong, or non-existent or that they compen-
sate for each other, and this result held in all considered
subgroups. For continuous outcomes, the observed 0.13 differ-
ence in standardized mean differences invites the two following
comments. First, although significant, the observed difference
can be considered moderate in view of previously reported dif-
ferences in standardized mean differences.26 Second, one could
have expected a difference in the opposite sense in view of the
underlying mechanisms (i.e. larger intervention effect estimates
in CRTs than in IRTs). A potential explanation is that there
are probably many single-centre IRTs, with low median size
(113 participants), whereas CRTs are intrinsically multicentre
studies, most randomizing practices, schools or classrooms.
The discrepancy we observed between MAs with binary
and continuous outcomes is not new, and others have urged
caution when extrapolating results of meta-epidemiological
studies of binary outcomes to situations of continuous out-
comes.24,26 We found several differences between trials and
MAs according to whether the outcome was continuous or
binary: (i) the sample size was smaller in trials with continu-
ous outcomes; (ii) heterogeneity was higher (median I2 of
60.4 compared with 26.5); (iii) blinding was less frequent;
(iv) outcomes were more frequently subjective (64.4% of
MAs with a continuous outcome vs 27.6% with a binary
outcome when focusing on only ‘subjective outcome’; and
(v) the settings differed, with cluster trials with a continuous
outcome being more likely to have non-clinical settings. All
these differences may explain the discrepancy we observed.
Finally, from a statistical point of view, we cannot ex-
clude some form of meta-confounding. We indeed adjusted
analyses, but doing so led to discarding some MAs (nota-
bly those with only three trials), and we adjusted on only
one covariate at a time.
Conclusions and implications
For binary outcomes, CRTs and IRTs produced the same
intervention effect estimates, but intervention effect esti-
mates were marginally more favourable (i.e. either more
beneficial or less detrimental) for IRTs with continuous
outcomes. However, this result was not observed for trials
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assessing a pharmacological intervention or with an objec-
tive outcome. More work is needed, in particular to under-
stand how the type of intervention, outcome, setting or
trial sample size affects the results.
Supplementary Data
Supplementary data are available at IJE online.
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